Expanding MRD testing to more patients with colorectal cancer
Latitude™ is a tissue-free, blood-based MRD test that delivers fast, reliable results without tumor tissue. Built on a targeted CRC-specific methylation panel, Latitude™ offers high sensitivity and specificity for detecting residual disease in CRC patients.
Learn how you can overcome tissue constraints by integrating Latitude™ into your clinical workflow
Latitude™ status post-surgery is highly prognostic
The clinical performance in a 195 patient, 1300+ samples CRC study using samples from the CIRCULATE-JAPAN GALAXY Study:
- Patients who tested negative with Latitude™ had significantly longer DFS compared to those who tested positive. HR ratio of 10, p<0.001.
- Median lead time of 4.6 months before radiographic relapse.
Latitude™ post-operatively is predictive of ACT benefit
Determine which patients will benefit from ACT:
- Patients who were Latitude™-negative derived little benefit from adjuvant chemotherapy (ACT), whereas Latitude™-positive patients experienced a clinical benefit from ACT.
How to order Latitude™
